Last reviewed · How we verify

Group D : Dexmedetomidine + propofol group

Seoul National University Hospital · FDA-approved active Small molecule

Dexmedetomidine and propofol are combined to provide sedation and anesthesia through alpha-2 adrenergic receptor agonism and GABA-A receptor potentiation, respectively.

Dexmedetomidine and propofol are combined to provide sedation and anesthesia through alpha-2 adrenergic receptor agonism and GABA-A receptor potentiation, respectively. Used for Sedation during anesthesia and mechanical ventilation in intensive care settings, Procedural sedation.

At a glance

Generic nameGroup D : Dexmedetomidine + propofol group
SponsorSeoul National University Hospital
Drug classSedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)
TargetAlpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesiology / Critical Care
PhaseFDA-approved

Mechanism of action

Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis while maintaining airway reflexes. Propofol is a GABA-A receptor positive allosteric modulator that induces rapid sedation and hypnosis. The combination is used clinically to achieve balanced sedation-anesthesia with potentially reduced dosing requirements and improved safety profiles compared to either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: